Neutralizing and cross-reacting antibodies: implications for immunotherapy and SARS-CoV-2 vaccine development
The novel coronavirus SARS-CoV-2 emerged in China in 2019 and quickly spread globally, causing a pandemic. There is an urgent need to develop vaccines against the virus, and both convalescent plasma and immune globulin are currently in clinical trials for treatment of patients with COVID-19. It is u...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-01-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2020.1787074 |
| _version_ | 1797633736297152512 |
|---|---|
| author | Samuel A. Cohen Caitlyn Kellogg Ozlem Equils |
| author_facet | Samuel A. Cohen Caitlyn Kellogg Ozlem Equils |
| author_sort | Samuel A. Cohen |
| collection | DOAJ |
| description | The novel coronavirus SARS-CoV-2 emerged in China in 2019 and quickly spread globally, causing a pandemic. There is an urgent need to develop vaccines against the virus, and both convalescent plasma and immune globulin are currently in clinical trials for treatment of patients with COVID-19. It is unclear whether antibodies induced by SARS-CoV-2 have neutralizing capacity and whether they can protect from future infection. Seasonal human coronaviruses (HCoV) have been circulating for decades. It is currently unknown whether antibodies against seasonal HCoV may cross-neutralize SARS-CoV-2. Data from neonates suggest that trans-placental antibodies against HCoV may have neutralizing capacity. Here we briefly review the epidemiologic observations on HCoV and discuss the potential implications for neutralizing and cross-neutralizing antibodies against SARS-CoV-2. |
| first_indexed | 2024-03-11T11:58:02Z |
| format | Article |
| id | doaj.art-afe1a874d5cc4b4c9e08a0dc88e9ef6d |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T11:58:02Z |
| publishDate | 2021-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-afe1a874d5cc4b4c9e08a0dc88e9ef6d2023-11-08T11:55:19ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2021-01-01171848710.1080/21645515.2020.17870741787074Neutralizing and cross-reacting antibodies: implications for immunotherapy and SARS-CoV-2 vaccine developmentSamuel A. Cohen0Caitlyn Kellogg1Ozlem Equils2Keck School of Medicine of USCPublic Health Nonprofit (www.miora.org)Public Health Nonprofit (www.miora.org)The novel coronavirus SARS-CoV-2 emerged in China in 2019 and quickly spread globally, causing a pandemic. There is an urgent need to develop vaccines against the virus, and both convalescent plasma and immune globulin are currently in clinical trials for treatment of patients with COVID-19. It is unclear whether antibodies induced by SARS-CoV-2 have neutralizing capacity and whether they can protect from future infection. Seasonal human coronaviruses (HCoV) have been circulating for decades. It is currently unknown whether antibodies against seasonal HCoV may cross-neutralize SARS-CoV-2. Data from neonates suggest that trans-placental antibodies against HCoV may have neutralizing capacity. Here we briefly review the epidemiologic observations on HCoV and discuss the potential implications for neutralizing and cross-neutralizing antibodies against SARS-CoV-2.http://dx.doi.org/10.1080/21645515.2020.1787074covid-19vaccineimmunotherapypregnancy |
| spellingShingle | Samuel A. Cohen Caitlyn Kellogg Ozlem Equils Neutralizing and cross-reacting antibodies: implications for immunotherapy and SARS-CoV-2 vaccine development Human Vaccines & Immunotherapeutics covid-19 vaccine immunotherapy pregnancy |
| title | Neutralizing and cross-reacting antibodies: implications for immunotherapy and SARS-CoV-2 vaccine development |
| title_full | Neutralizing and cross-reacting antibodies: implications for immunotherapy and SARS-CoV-2 vaccine development |
| title_fullStr | Neutralizing and cross-reacting antibodies: implications for immunotherapy and SARS-CoV-2 vaccine development |
| title_full_unstemmed | Neutralizing and cross-reacting antibodies: implications for immunotherapy and SARS-CoV-2 vaccine development |
| title_short | Neutralizing and cross-reacting antibodies: implications for immunotherapy and SARS-CoV-2 vaccine development |
| title_sort | neutralizing and cross reacting antibodies implications for immunotherapy and sars cov 2 vaccine development |
| topic | covid-19 vaccine immunotherapy pregnancy |
| url | http://dx.doi.org/10.1080/21645515.2020.1787074 |
| work_keys_str_mv | AT samuelacohen neutralizingandcrossreactingantibodiesimplicationsforimmunotherapyandsarscov2vaccinedevelopment AT caitlynkellogg neutralizingandcrossreactingantibodiesimplicationsforimmunotherapyandsarscov2vaccinedevelopment AT ozlemequils neutralizingandcrossreactingantibodiesimplicationsforimmunotherapyandsarscov2vaccinedevelopment |